In a patient recently treated with oral vancomycin who now has a stool specimen showing low Clostridioides difficile growth, should I repeat testing and start additional therapy, and what is the recommended treatment if the patient is symptomatic?

Management of C. difficile with Low Growth After Recent Vancomycin Treatment

Do not repeat testing if the patient is asymptomatic, and if symptomatic with persistent diarrhea, treat this as a first recurrence with either a tapered and pulsed vancomycin regimen or fidaxomicin rather than repeating a standard 10-day vancomycin course 1.

Key Decision Points

Testing Strategy

The finding of "low growth" C. difficile after recent vancomycin treatment requires careful interpretation:

• Do not perform routine test of cure after completing CDI treatment 2. Testing should only occur if there are persistent or worsening diarrheal symptoms.
• C. difficile colonization (positive test without symptoms) does not require treatment 1.
• If the patient is asymptomatic, this likely represents colonization or residual organism detection rather than active infection—no treatment is indicated.

If the Patient is Symptomatic

This scenario represents a first recurrence (second CDI episode), which occurs in 18-25% of patients after vancomycin treatment 3. The IDSA/SHEA 2018 guidelines provide three treatment options 1:

Option 1 (Preferred): Tapered and pulsed vancomycin regimen

• 125 mg four times daily for 10-14 days
• Then 125 mg twice daily for 7 days
• Then 125 mg once daily for 7 days
• Then 125 mg every 2-3 days for 2-8 weeks

Option 2: Fidaxomicin 200 mg twice daily for 10 days (lower recurrence rates make this favorable if available) 1, 2

Option 3: Standard vancomycin 125 mg four times daily for 10 days (only if metronidazole was used initially—not applicable here)

Critical Timing Consideration

Research demonstrates a vulnerable period for C. difficile recolonization that extends approximately 3 weeks after completing vancomycin treatment 4:

• Vancomycin maintains inhibitory stool concentrations for 4-5 days post-therapy
• From day 5 through days 14-21, the gut microbiota remains severely disrupted and unable to resist C. difficile
• By 21-28 days post-treatment, most patients regain colonization resistance

This explains why your patient with "low growth" shortly after vancomycin may be at high risk for full recurrence.

Severity Assessment

If treating, classify disease severity to guide intensity of therapy 1, 2:

• Non-severe: WBC ≤15,000/mm³ AND creatinine <1.5 mg/dL
• Severe: WBC ≥15,000/mm³ OR creatinine >1.5 mg/dL
• Fulminant: Hypotension, shock, ileus, or megacolon

For severe disease, use vancomycin 125 mg four times daily or fidaxomicin. For fulminant disease, escalate to vancomycin 500 mg four times daily plus IV metronidazole 1.

Prevention of Further Recurrence

After treating this first recurrence, strongly consider fecal microbiota-based therapy if a second recurrence occurs (third total episode) 1, 2. Options include:

• Fecal microbiota transplantation (FMT)
• FDA-approved products: fecal microbiota spores, live-brpk or fecal microbiota, live-jslm

Common Pitfalls

• Avoid repeating standard 10-day vancomycin courses for recurrences—this increases risk of subsequent recurrences 1
• Do not use metronidazole for recurrent disease due to inferior efficacy and neurotoxicity risk with repeated courses 1
• Do not test asymptomatic patients—positive tests represent colonization, not infection 2, 5
• Discontinue the inciting antibiotic if still being administered, as this strongly influences recurrence risk 1